Arcutis Biotherapeutics Inc (NASDAQ: ARQT) made a new high in yesterday’s trading session. This came just a day after the company announced that Heather Rowe had joined the company as the Vice President in charge of investor relations and corporate communications.

Heather Armstrong will be tasked with communicating the company’s corporate objectives and successes to the relevant stakeholders. They include shareholders, the global investor community, employees, and the media. According to the company’s Chief Financial Officer, John Smither, Heather has over 16 years’ experience in strategic communication and has a good record in developing and implementing strategic communication. Smither also added that Ms. Heather’s communication experience especially in biopharma, and more so in dermatology, makes her the best person for the job at Arcutis.

Heather’s appointment came just a few days after the company announced data from its phase 2b study of topical roflumilast cream in people suffering from plaque psoriasis. In announcing the data, CEO Howard Welgus stated that the company was happy to have taken part in the scientific exchange during the 2020 AAD meeting. He also added that patients and doctors need an innovative topical treatment option that is more effective, safe and tolerable to people with plaque psoriasis. Welgus also stated that the company was looking forward to sharing data that would show how topical roflumilast cream could act as an effective daily treatment if approved. He concluded by stating that its effectiveness took care of all the challenges currently encountered in the treatment of plaque psoriasis.

ARQT opened the day at $28.99. It then traded between a low of $28.55 and a high of $34 before closing at $30.53.  Volumes in the day stood at 196.56k.

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc is a biopharma company that focuses on dermatological treatments. It is based in Westlake Village, California.